EXELIXIS INC (EXEL) Stock Fundamental Analysis
NASDAQ:EXEL • US30161Q1040
44.095 USD
+0.17 (+0.4%)
Last: Feb 17, 2026, 03:59 PM
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EXEL may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, EXEL could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year EXEL was profitable.
- In the past year EXEL had a positive cash flow from operations.
- In the past 5 years EXEL has always been profitable.
- In the past 5 years EXEL always reported a positive cash flow from operatings.
1.2 Ratios
- EXEL has a Return On Assets of 27.51%. This is amongst the best in the industry. EXEL outperforms 97.70% of its industry peers.
- EXEL has a better Return On Equity (36.21%) than 97.89% of its industry peers.
- EXEL has a better Return On Invested Capital (29.21%) than 98.85% of its industry peers.
- EXEL had an Average Return On Invested Capital over the past 3 years of 18.74%. This is in line with the industry average of 18.54%.
- The 3 year average ROIC (18.74%) for EXEL is below the current ROIC(29.21%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROIC | 29.21% |
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
1.3 Margins
- EXEL's Profit Margin of 33.73% is amongst the best of the industry. EXEL outperforms 96.55% of its industry peers.
- EXEL's Profit Margin has improved in the last couple of years.
- EXEL has a better Operating Margin (38.48%) than 97.89% of its industry peers.
- In the last couple of years the Operating Margin of EXEL has grown nicely.
- The Gross Margin of EXEL (96.39%) is better than 96.35% of its industry peers.
- EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% |
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
- EXEL has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, EXEL has less shares outstanding
- There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 12.59 indicates that EXEL is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 12.59, EXEL belongs to the top of the industry, outperforming 84.84% of the companies in the same industry.
- EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.59 |
ROIC/WACC3.37
WACC8.68%
2.3 Liquidity
- EXEL has a Current Ratio of 3.56. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
- EXEL has a Current ratio of 3.56. This is comparable to the rest of the industry: EXEL outperforms 42.61% of its industry peers.
- EXEL has a Quick Ratio of 3.50. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
- EXEL has a Quick ratio of 3.50. This is comparable to the rest of the industry: EXEL outperforms 44.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 |
3. Growth
3.1 Past
- EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.73%, which is quite impressive.
- The Earnings Per Share has been growing by 51.25% on average over the past years. This is a very strong growth
- The Revenue has been growing slightly by 6.98% in the past year.
- Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 18.63% on average per year.
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
3.2 Future
- The Earnings Per Share is expected to grow by 15.92% on average over the next years. This is quite good.
- The Revenue is expected to grow by 7.52% on average over the next years.
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 15.92, which indicates a correct valuation of EXEL.
- EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.78% of the companies in the same industry.
- EXEL is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 13.57 indicates a correct valuation of EXEL.
- Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.55% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.06. EXEL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.92 | ||
| Fwd PE | 13.57 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.74% of the companies listed in the same industry.
- EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 97.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.5 | ||
| EV/EBITDA | 11 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of EXEL may justify a higher PE ratio.
- EXEL's earnings are expected to grow with 19.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.92
PEG (5Y)0.31
EPS Next 2Y21.2%
EPS Next 3Y19.22%
5. Dividend
5.1 Amount
- No dividends for EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:EXEL (2/17/2026, 3:59:09 PM)
44.095
+0.17 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2026-02-10/amc
Earnings (Next)05-11 2026-05-11/amc
Inst Owners97.46%
Inst Owner Change-0.9%
Ins Owners2.18%
Ins Owner Change4.47%
Market Cap11.82B
Revenue(TTM)2.32B
Net Income(TTM)782.57M
Analysts74.81
Price Target46.75 (6.02%)
Short Float %10.66%
Short Ratio10.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.16%
Min EPS beat(2)7.04%
Max EPS beat(2)9.27%
EPS beat(4)4
Avg EPS beat(4)19.83%
Min EPS beat(4)7.04%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)29.32%
EPS beat(12)9
Avg EPS beat(12)15.98%
EPS beat(16)13
Avg EPS beat(16)18.75%
Revenue beat(2)0
Avg Revenue beat(2)-1.79%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)0.68%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.27%
Revenue beat(12)4
Avg Revenue beat(12)2.32%
Revenue beat(16)6
Avg Revenue beat(16)1.65%
PT rev (1m)1.23%
PT rev (3m)4.42%
EPS NQ rev (1m)11.57%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)1.7%
EPS NY rev (3m)13.74%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.92 | ||
| Fwd PE | 13.57 | ||
| P/S | 5.1 | ||
| P/FCF | 13.5 | ||
| P/OCF | 13.37 | ||
| P/B | 5.47 | ||
| P/tB | 5.64 | ||
| EV/EBITDA | 11 |
EPS(TTM)2.77
EY6.28%
EPS(NY)3.25
Fwd EY7.37%
FCF(TTM)3.27
FCFY7.41%
OCF(TTM)3.3
OCFY7.48%
SpS8.65
BVpS8.06
TBVpS7.82
PEG (NY)0.92
PEG (5Y)0.31
Graham Number22.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROCE | 36.6% | ||
| ROIC | 29.21% | ||
| ROICexc | 51.64% | ||
| ROICexgc | 54.14% | ||
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% | ||
| FCFM | 37.75% |
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
ROICexc(3y)32.95%
ROICexc(5y)27.65%
ROICexgc(3y)34.51%
ROICexgc(5y)29.16%
ROCE(3y)23.48%
ROCE(5y)18.07%
ROICexgc growth 3Y66.65%
ROICexgc growth 5Y32.48%
ROICexc growth 3Y66.54%
ROICexc growth 5Y33.67%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 29.01% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.93% | ||
| Profit Quality | 111.92% | ||
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 | ||
| Altman-Z | 12.59 |
F-Score7
WACC8.68%
ROIC/WACC3.37
Cap/Depr(3y)95.03%
Cap/Depr(5y)177.94%
Cap/Sales(3y)1.3%
Cap/Sales(5y)2.02%
Profit Quality(3y)127.23%
Profit Quality(5y)142.21%
High Growth Momentum
Growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
EBIT growth 1Y29.39%
EBIT growth 3Y64.24%
EBIT growth 5Y51.98%
EBIT Next Year12.21%
EBIT Next 3Y-11.05%
EBIT Next 5Y-5.67%
FCF growth 1Y30.42%
FCF growth 3Y37.77%
FCF growth 5Y37.42%
OCF growth 1Y26.33%
OCF growth 3Y34.6%
OCF growth 5Y33.44%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 9 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 17.33% in the next year.